An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.
An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to...
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.
Open the app view to save this story, compare related coverage, and continue from the same source.